Phase II Win For Merck KGaA/Avillion Psoriasis Drug May Be Too Late

Sonelokinab Targets Both IL-17A and IL-17F

The German major is looking for a partner to advance its IL-17A/IL-17F nanobody sonelokinab for psoriasis but the search could be tricky given the strength of Novartis's Cosentyx and Eli Lilly's Taltz, while UCB's IL-17A and IL-17F inhibitor bimekizumab is likely to be approved soon.

Psoriasis
Search still on for new psoriasis therapies • Source: Shutterstock

Merck KGaA and Avillion LLP have presented positive mid-stage data on the psoriasis drug sonelokinab which has had a chequered history and still faces an uphill task in making it into a highly competitive market.

The German firm and its UK partner have released topline results of a Phase II trial of sonelokinab (also known...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category